PRQR(PRQR)
PRQR
ANALYST COVERAGE10 analysts
BUY
▲ +160.4%upside to target
L $2.00
Med $3.75consensus
H $5.00Key MetricsTTM
Market Cap$130.51M
Revenue TTM$13.44M
Net Income TTM-$45.62M
Free Cash Flow-$48.99M
Gross Margin89.7%
Operating Margin-345.5%
Net Margin-339.4%
Return on Equity-86.5%
Return on Assets-46.0%
Debt / Equity0.36
Current Ratio2.48
EPS TTM$-0.43
PRICE
Prev Close
1.43
Open
1.42
Day Range1.42 – 1.47
1.42
1.47
52W Range1.33 – 3.10
1.33
3.10
6% of range
VOLUME & SIZE
Avg Volume
566.9K
FUNDAMENTALS
P/E Ratio
-2.9x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
TECHNICAL
RSI (14)
39
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
PRQR News
About
proqr therapeutics is a leiden, nl based biotech company focused on developments of drugs to treat genetic disorders. based on a novel proprietary technology we discover and develop drugs to change the lives of patients around the world. founded by industry icons and based on ground breaking science we strive to make a meaningful impact. check out our website for vacancies: www.proqr.com
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Daniel De Boer
Country
Netherlands
Website
Daniel Anton de BoerFounder, CEO & Executive Director
Sandra van der KolkJunior Financial Controller
Sarah Cue KielyVice President of Investor Relations & Corporate Communications
Gerard PlatenburgCo-Founder, Chief Scientific Officer & Executive Director
Dennis HomChief Financial Officer
Sheila SponseleeChief People & Operations Officer
Cristina Lopez LopezChief Medical Officer